Fri, Aug 1, 2014, 11:30 AM EDT - U.S. Markets close in 4 hrs 30 mins

Recent

% | $
Click the to save as a favorite.

SIGA Technologies, Inc. Message Board

truont2 13 posts  |  Last Activity: Jul 23, 2014 3:29 PM Member since: May 28, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • truont2 truont2 Jul 23, 2014 3:29 PM Flag

    CEO owns 35%-40% of outstanding shares and if you look into his recent interviews he states clearly that he does not like dilution. This company is low key and operates almost like a private company.

    Sentiment: Buy

  • Reply to

    COLTON

    by shortstompen Jun 29, 2014 3:13 AM
    truont2 truont2 Jun 29, 2014 5:05 AM Flag

    Keep shorting Colton. Tell all your buddies to short as well. I want a bear raid on Monday so I can get another 20% cushion.

    Sentiment: Buy

  • Reply to

    Four up catalyts still to come

    by theeseer Jun 5, 2014 5:15 PM
    truont2 truont2 Jun 5, 2014 5:37 PM Flag

    Agreed. The Board even said during the shareholder meeting "no more CRLs." I usually sit in these type of conference calls with the Government and can definitely tell if my application is going to be rejected or going to be approved. In the conference call they hinted the FDA may approve labeling before the official date. I wanted to add 5. Technosphere trials with other drugs (pain relief, COPD etc....limitless pending moiety).

  • Reply to

    Over the last year this stock:

    by ri66 Jun 27, 2014 2:02 PM
    truont2 truont2 Jun 30, 2014 10:43 AM Flag

    Accidental discovery prompted FDA to guide them on additional indications. Management and FDA are working together for a hyaluronic acid alternative.

    Sentiment: Strong Buy

  • Reply to

    Short Interest now up to 6,000,000 shares...

    by superforce_57 Jun 26, 2014 10:21 AM
    truont2 truont2 Jun 26, 2014 11:16 AM Flag

    Look at the SPRING results published in several journals. The STEP 12 week results are going to be released very soon as well. AMPIO accidentally stumbled on a theurapeutic that activates healing pathways and the FDA is very interested. If STEP results show any type of regeneration it will be a blockbuster. Indications for other parts of the body will follow.

    Sentiment: Strong Buy

  • truont2 truont2 Jun 29, 2014 5:32 AM Flag

    The market is going to shift from prandial needle to prandial inhaler. Is there a prandial inhaler competitor to Afrezza yet? Nope...so enjoy the show. This is akin to a Tesla moment in share prices. You could also do a case study of Exubera being a first to market failure. Afrezza would have studied all the ins and outs of why Exubera failed and will become the dominant second to market. This is disruptive technology and I love the denial. Just like everyone not seeing a place for a personal computer or a smartphone...and like all early deniers they will all eventually become late adopters. These are exciting times in the diabetic market.

    Sentiment: Buy

  • truont2 truont2 Jun 29, 2014 5:55 AM Flag

    Read some of the recent conference transcripts. Management says "easily a blockbuster." The inhaler itself is cheap and the technosphere application is huge. $10-$11 is incredibly cheap. I see it going to $30-40 on insulin alone. Future: Think of rapid pain relief or vaccines. Think of a long acting existing drug that has the correct moiety for technosphere and you can add another $10-20.

    Sentiment: Buy

  • truont2 truont2 Jun 29, 2014 5:49 AM Flag

    Cite Exubera as a first to market failure. We all know the statistics of success for the 2nd product that comes to market...and it is usually largest market penetration and growth. Your arguments are actually in favour of Afrezza because Afrezza will have studied Exubra extensively to avoid the same results.

    Sentiment: Buy

  • Reply to

    confused

    by stacyratajczyk Jun 5, 2014 1:54 PM
    truont2 truont2 Jun 5, 2014 2:47 PM Flag

    Look up MNKD 2014 shareholder meeting, put on headphones and listen to part 3 via youtube. An investor flat out asks for "signals from the FDA" you will hear no more CRLs, a recent conference call and you will understand an approval is soon.

  • Reply to

    the crazy price action yesterday in a nutshell

    by waiting4kerx Jun 28, 2014 10:12 AM
    truont2 truont2 Jun 28, 2014 6:56 PM Flag

    I work at retail HQ and did a small test. Did the "did you hear an insulin inhaler" was approved by the FDA yesterday and the response was amazing. It's the diabetic "EpiPen," and will be a part of most younger diabetics lifestyles. Take a puff and eat...it's that easy. Or, going out tonight with friends for dinner? Bring afrezza. Its pharmacokinetics/dynamics will make it a winner for sure

    Sentiment: Buy

  • Reply to

    Support

    by awana_moorehead Jun 5, 2014 10:51 AM
    truont2 truont2 Jun 5, 2014 11:16 AM Flag

    It will hit $20 as soon as the market reads more into the shareholder meeting + massive short squeeze. In corporate lingo, the board already said no more CRLs via FDA conference call which means only label finalization. A partnership will be announced soon as well with large upfront payments. Another thing to note is MNKD's expansion into rapid pain relief with the same technology. Say goodbye to slow acting pills. Just go check the youtube recordings and user forums for more info.

  • truont2 truont2 Jun 29, 2014 6:05 AM Flag

    Good selling features: rapid effect, shelf-stable, ease of use, small and convenient, can be effectively combined with basal, can be used in early stages to protect pancreas function, little to no weight gain

    Bad selling features: easy to lose, inhaler and cartridges are cheap to make and will litter landfills, but MNKD can have a sustainability plan in place to recycle one day. need to increase units for the ones that really really need it (3 greens might not be enough for some).

    Sentiment: Buy

  • Reply to

    Us Longs are SOOOOOOO stupid

    by str417lasd Jun 28, 2014 11:36 PM
    truont2 truont2 Jun 29, 2014 5:45 AM Flag

    Fundamentals haven't changed for MNKD. Economic moat: insulin inhaler delivery/technosphere and rapid pharmokinetics/dynamics, soon pediatric market and pain relief. Next event: partnership or buyout. From the recent calls I suspect a licensing deal for particular countries to Afrezza with large upfront payments and double digit royalties. But, if the negotiations are not in the bidders favour they will try to outright buy MNKD. MNKD understandably wants to retain all rights to technosphere so they can begin their pain relief strategy. I'll speculate a little and say MNKD could look into vaccines and military applications which desperately need to move out of needles.

    Sentiment: Buy

SIGA
2.55-0.09(-3.41%)11:29 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.